Edison Initiates ADR Coverage on DBV Technologies

News provided by

Nov 18, 2014, 11:50 ET

LONDON, November 18, 2014 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage on the US-listed ADRs of DBV Technologies (NASDAQ:DBVT), the French allergy company focused on peanut allergy.

(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

DBV Technologies (DBV) is a French allergy company focused on the development of disease-modifying, potential cures for various food allergies. DBV's Viaskin patch technology offers a novel delivery in allergy immunotherapy, by exposing the immune system to allergens through the skin but without passage to the blood. This reduces the risk of life-threatening immune reactions such as anaphylaxis. The Viaskin technology is particularly relevant in peanut allergy, which can have fatal consequences and where no treatment options exist aside from strict avoidance and carrying an adrenaline pen.

Our valuation is $1,379m, or $36.5/ADS, which reflects a 60% probability of success following the positive Phase II VIPES data, commensurate with a Phase III asset. In addition, our valuation assumes DBV will commercialize alone in the US. Our Viaskin Peanut peak sales are $2.4bn in the US and Europe. Cash of around $158m post the global fund-raise could potentially provide a cash runway all the way through to profitability.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:

LinkedIn - http://www.linkedin.com/company/edison-investment-research

Twitter - http://www.twitter.com/Edison_Inv_Res

YouTube - http://www.youtube.com/edisonitv

Frankfurt
+49(0)69-78-8076-960
Schumannstrasse 34b
60325 Frankfurt
Germany

London
+44(0)20-3077-5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York
+1-646-653-7026
245 Park Avenue, 39th Floor
10167, New York
US

Sydney
+61(0)2-9258-1161
Level 25, Aurora Place
88 Phillip St, Sydney
NSW 2000, Australia

Wellington
+64(0)4-8948-555
Level 15, 171 Featherston St
Wellington 6011
New Zealand

SOURCE Edison Investment Research